MSB 1.86% $1.32 mesoblast limited

Tracking Valuations, page-23

  1. 11,249 Posts.
    lightbulb Created with Sketch. 29638
    I didn't want to give specific timeframes. This is what I said:

    • Risk-adjusted value @ $8.85 for Adult GVHD, Pediatric GVHD and COVID ARDS
      (potential future target for this group @ $17)
    A good outcome from the COVID ARDS trial could move us to $8.85 ballpark relatively quickly. As for the $17 valuation ... the market is forward-looking and it really comes down to timelines for commercialisation of Pediatric and Adult GVHD treatment ( these make up about 30% of the overall $17 valuation ). My perspective is that once revenues are coming in for Pediatric GVHD, the market will start to price in revenues for Adult GVHD.

    Note - Advanced Heart Failure and Chronic Low Back Pain are not included in the $17 target and we have reports from trials expected around mid year.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.32
Change
-0.025(1.86%)
Mkt cap ! $1.507B
Open High Low Value Volume
$1.35 $1.35 $1.31 $2.699M 2.040M

Buyers (Bids)

No. Vol. Price($)
2 34995 $1.32
 

Sellers (Offers)

Price($) Vol. No.
$1.33 10374 2
View Market Depth
Last trade - 16.10pm 31/10/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.